



**Stock Code:6527**

**Crystalvue Medical Corporation  
Notice of 2024 Annual General Shareholders' Meeting  
(Summary Translation)**

- I. The 2024 Annual General Shareholders' Meeting (the "Meeting") will be held at 9:00 a.m. on Friday, May 24, 2024 at Fullon Hotel Taoyuan (No. 200, Section 1, Dashingshi Road, Taoyuan District, Taoyuan City, Taiwan, Republic of China (R.O.C.)).

**Agenda**

**1. Report Items**

- (1) 2023 Business Report.
- (2) Audit Committee's Review Report of 2023.
- (3) Remuneration distribution to employees and directors for 2023.
- (4) Amendment to the "The Rule of Operation of Board Meetings".
- (5) Amendment to the "Corporate Social Responsibility Practice Principles".
- (6) Implementation of private placement of common stock.

**2. Proposed Resolutions**

- (1) 2023 Business Report and Financial Statements.
- (2) Distribution of 2023 Profits.

**3. Discussions and Election**

- (1) Election of the 7th term Board of Directors.
- (2) Proposal for Release the Prohibition on the 7th term of Board of Directors from Participation in Competitive Business.
- (3) Amendment to the "Articles of Incorporation".

**4. Other Business and Special Motion**

- II. The proposal for distribution of 2023 earnings adopted at the meeting of the Board of Directors is as follows:

Cash dividends: the proposed dividend is NT\$ 2.07 per share.

- III. The company should elect 8 directors. (Contains 4 independent directors.) The list of candidates for the nomination system for the directors and independent directors: The Directors are Wai Wang, Chung-Ping Chuang, VISCO VISION INC. Representative: Chong-Yi Li, AZ Venture Partner Limited Representative:

Chih-Ting Kao, and the Independent Directors are: Wan-Ying Lin, En-Hsu Huang, Shih-Chi Chou, Fu-Ci Siang.

To view related information such as educational background/ work experience, please go to Market Observation Post System. (<http://mops.twse.com.tw>)

- IV. Under the premise of the resolution in accordance with Article 209 of the Company Act, hereby proposes for the removal of restrictions on non-competition obligation for newly elected directors and their representatives.

For the concurrent positions of newly elected directors, please refer to the meeting agenda.

- V. We hereby issue this letter together with an Attendance Notice of the Meeting and a Proxy Attendance Form. To attend the Meeting in person, please sign or stamp on the Attendance Notice and register in person at the Meeting on the scheduled meeting date; to attend by proxy, please fill out and return the Proxy Attendance Form. In order to be valid, the Proxy Attendance Form shall be delivered to the Stock Transfer Agency Department of Mega Securities Co., Ltd. five days prior to the Meeting.

- VI. The Company will compile and post a general list of information on calls for proxies, if any, 30 days before the Meeting, on the Securities & Futures Institute website (<http://free.sfi.org.tw>). Investors may search information on the above site.

- VII. Should there be items related to article 172 of the Company Act, Article 26-1 and 43-6 of Securities and Exchange Act or other relevant laws and regulations will be posted on the Market Observation Post System under icon: Electronic Books / Shareholders' meetings / Stock code 6527 / Year 2024 (<https://emops.twse.com.tw>) and Company website.

- VIII. Of this Meeting, the statistic verification agency of the Power of Attorney will be Mega Securities Co., Ltd. (Stock Transfer Agency Department).

- IX. Voting rights for the Meeting can be exercised via electronic form during the period from April 24, 2024 to May 21, 2024. Please access "Shareholder e-voting" at the website of Taiwan Depository & Clearing Corporation (<https://www.stockvote.com.tw>).

- X. No souvenir will be offered in the Meeting.

Sincerely,

Board of Directors

Crystalvue Medical Corporation